{"id":"W4214935792","doi":"10.1016/j.esmoop.2022.100410","title":"Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Chugai Pharmaceutical; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Janssen Research and Development; EMD Serono; Genentech; Ipsen; PharmaMar; Astellas Pharma; National Institute for Health and Care Research; Seagen; G1 Therapeutics; AstraZeneca España; Daiichi-Sankyo; ViewRay; BeiGene; Meso Scale Diagnostics; Les Laboratories Pierre Fabre; TG Therapeutics; Amgen; Boehringer Ingelheim; Elekta; Taiho Pharmaceutical; Mirati Therapeutics; Varian Medical Systems; Takeda Pharmaceutical Company; AbbVie; Sanofi; Celgene; Novartis; Manchester Biomedical Research Centre; Merck; GlaxoSmithKline; Daiichi Sankyo Europe; Servier; Bayer; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; AstraZeneca; Incyte; Pfizer; Roche; Astellas Pharma US","keywords":"Durvalumab; Medicine; Chemoradiotherapy; Hazard ratio; Clinical endpoint; Internal medicine; Post-hoc analysis; Stage (stratigraphy); Oncology; Lung cancer; Cancer; Clinical trial; Confidence interval; Pembrolizumab; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004087114,0.0002385683,0.0007254583,0.0001087119,0.0001724253,0.0001131102,0.000414319,0.00004045161,0.004540338],"category_scores_gemma":[0.000003624153,0.0001459799,0.000156212,0.0006165003,0.00003862772,0.0001588867,0.000162644,0.000247456,0.000004361324],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007786185,"about_ca_system_score_gemma":0.0004261191,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.02493383,"about_ca_topic_score_gemma":0.02718504,"domain_scores_codex":[0.9983032,0.0002149896,0.0002917146,0.000540054,0.0003824026,0.0002676682],"domain_scores_gemma":[0.9987448,0.0001043185,0.000139178,0.0008645331,0.00003197382,0.000115165],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01308788,0.001019261,0.9756967,0.00001296683,0.00168134,0.0002030089,0.006278154,0.0003271979,0.000005891403,0.000003389998,0.00110028,0.0005838933],"study_design_scores_gemma":[0.0860191,0.001099668,0.8970167,0.00004846389,0.002009117,9.227807e-7,0.004879962,0.0005408014,0.000317537,0.000005441006,0.007741102,0.0003211669],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928555,0.0008454067,0.00001184938,0.00271837,0.0002037538,0.002465911,0.0002311701,0.00002099667,0.0006469862],"genre_scores_gemma":[0.9901112,0.0002864505,0.0001803201,0.001566453,0.000138421,0.005881331,0.0001788409,0.00004570598,0.00161127],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07868002,"threshold_uncertainty_score":0.9963697,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02197590166635086,"score_gpt":0.3131541527190675,"score_spread":0.2911782510527167,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}